CAS 89793-12-4;ethyl 2-chloropyrimidine-5-carboxylate

Produktname:ethyl 2-chloropyrimidine-5-carboxylate

IUPAC Name:ethyl 2-chloropyrimidine-5-carboxylate

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM108980-25g	in stock	ȎŢ
CM108980-100g	in stock	ǤĽŉ
CM108980-500g	in stock	ƓǵƓŢ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 89793-12-4 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:89793-12-4; Molekulare Formel:C7H7ClN2O2; Schmelzpunkt:-; SMILES-Code:O=C(C1=CN=C(Cl)N=C1)OCC; Dichte:

: Katalognummer:CM108980; Molekulargewicht:186.6; Siedepunkt:314.2°C at 760 mmHg; Mdl-Nr.:MFCD09863164; Lagerung:Keep in a tight container and store at ambient temperature

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Avapritinib; Blueprint Medicines announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.  AYVAKYT was designed to potently and selectively target KIT D816V, the primary underlying driver of the disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.